# Matinas BioPharma Holdings, Inc. (MTNB) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_07c719e2c416019b679a · retrieved 2026-08-11T16:04:51.878Z

## Overview
Matinas BioPharma Holdings, Inc. is a pharmaceutical company engaged in the development and commercialization of pharmaceutical preparations.

On July 23, 2026, BTIG, LLC terminated its At-The-Market Sales Agreement with Matinas BioPharma Holdings, Inc., effective immediately. The agreement, originally entered into on July 2, 2020, had permitted the Company to offer and sell up to $50,000,000 of common stock through BTIG in at-the-market offerings. The Company is not subject to any termination penalties or other expenses related to the termination.

## Terms
- Counterparty: BTIG, LLC · Deal value: $50.0M

## Key dates
- Announced 2026-07-24

## Timeline
- 2026-07-24 · 8-K (0001493152-26-034601): 8-K - Matinas BioPharma Holdings, Inc. — *Matinas BioPharma Holdings, Inc. is a pharmaceutical company engaged in the development and commercialization of pharmaceutical preparations.* On July 23, 2026, BTIG, LLC terminated its At-The-Market Sales Agreement with Matinas BioPharma Holdings, Inc., effective immediately. The agreement, originally entered into on July 2, 2020, had permitted the Company to offer and sell up to $50,000,000 of common stock through BTIG in at-the-market offerings. The Company is not subject to any termination penalties or other expenses related to the termination.
  https://www.sec.gov/Archives/edgar/data/1582554/0001493152-26-034601.txt

## Citations
- 0001493152-26-034601 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226034601